Neurogastrx
7EmployeesUS Form 5500 (plan participants) · Dec 2024
Facts
as of Nov 17, 2026Neurogastrx, Inc.. Thank you for visiting the website for Neurogastrx, Inc. ("Company"), a privately held, late clinical-stage biopharmaceutical company formerly headquartered in Woburn, MA.
- Legal name
- Neurogastrx, Inc.
- Headquarters
- Woburn, United States
- Founded
- 2017
- Employees
- 7US Form 5500 (plan participants) · Dec 2024
- Register numbers
- NAME neurogastrx inc
- Official records
- SEC CIK 1870700
- Website
- neurogastrx.com
These are the key facts about Neurogastrx on Alion as of Nov 17, 2026. Neurogastrx is headquartered in Woburn, United States. It was founded in 2017. It has raised $80M in 2 funding rounds. The latest round is Venture - Series Unknown of $60M, announced in 2021.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Neurogastrx, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Woburn United States | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$80MTotal raised
Venture - Series UnknownLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
$60M
$20M
Sources: funding announcements, grant and company registers
Milestones
Jun 25, 2021
Raised a round Venture round $60M · SEC Form D
Jun 18, 2021
Raised a round Venture round $20M · SEC Form D
2017
Founded
Each milestone is dated by its source: registers, filings, the press
Newsroom
Nov 7, 20252025
Oct 7, 20252025
News · markets.businessinsider.com
Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing A...
Oct 16, 20242024
Sources: the outlets named on each headline, each story once
